Figures & data
Figure 1. Flow chart of the population enrolled in the study.
Figure 2. ANA presence at T0, T1, and T2.
The ANA presence was evaluated at T0 (before the vaccination), at T1 (after 2 doses of vaccine) and at T2 (after the booster dose). The graph shows a statistically significant increase of ANA presence from T1 to T2 (** p < 0.05).
Figure 3. Pattern distribution of ANA positive samples at T1 and T2 (A, C, D, E). representative picture of a homogeneous positive sample at T2 (B).
The tables and the graphs summarised the relative percentage of the total patterns identified at T1 (A, D) and T2 (C, E). Patient4 resulted positive at T1 but negative at T2. The homogeneous pattern was observed in 50% of the positive samples at T1 and 42,86% at T2. The speckled one was detected in 40% at T1 and 21,43% at T2 and the cytoplasmatic in 10% and 3,57% respectively. In addition, at T2, the 7,14% of the samples had a nucleolar pattern, whereas the 25% showed other types of ANA positivity.
Figure 4. Distribution of positive blood autoimmunity tests at T0 and T1.
The presence of the blood autoimmunity markers was evaluated at T0 (before the vaccination), at T1 (after 2 doses of vaccine). RF: rheumatoid factor; MPO: myeloperoxidase; PR3: proteinase 3; CCP: anti-citrullinated peptide antibodies; ASMA:-alpha smooth muscle actin; aCL: cardiolipin; aB2: betaglycoprotein.
Data availability statement
The data that support the findings of this study are available from the corresponding author, [MCS], upon reasonable request.